Document Detail


Post-transcriptional regulation of placenta growth factor mRNA by hydrogen peroxide.
MedLine Citation:
PMID:  22683469     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In tissues containing pre-existing collateral vessels, occlusion of an upstream supply artery results in diversion of blood flow through these vessels, protecting the distal tissue from ischemia. The sudden rise in blood flow through collateral vessels exerts shear stress upon the vessel wall, thereby providing the initial stimulus for arteriogenesis. Arteriogenesis, the structural expansion of collateral circulation, involves smooth muscle cell (SMC) proliferation which leads to increased vessel diameter and wall thickness. Since shear is sensed at the level of endothelial cells (EC), communication from EC to the underlying SMC must occur as part of this process. We previously reported that endothelial cells (EC) exposed to shear stress release hydrogen peroxide (H(2)O(2)), and that H(2)O(2) can signal vascular SMC to increase gene and protein expression of placenta growth factor (PLGF), a known mediator of arteriogenesis. The purpose of the current study was to further elucidate the mechanism whereby PLGF is regulated by H(2)O(2). We found that a single, physiological dose of H(2)O(2) increases PLGF mRNA half-life, but has no effect on PLGF promoter activity, in human coronary artery SMC (CASMC). We further demonstrated that the H(2)O(2)-induced increase in PLGF mRNA levels partially relies on p38 MAPK, JNK and ERK1/2 pathways. Finally, we showed that chronic exposure to pathological levels of H(2)O(2) further increases PLGF mRNA levels, but does not result in a corresponding increase in PLGF secreted protein. These data suggest that PLGF regulation has an important translational component. To our knowledge, this is the first study to characterize post-transcriptional regulation of PLGF mRNA by H(2)O(2) in vascular SMC. These findings provide new insights into the regulation of this important growth factor and increase our understanding of PLGF-driven arteriogenesis.
Authors:
Jennifer H Shaw; Pamela G Lloyd
Related Documents :
16640639 - Quantification of neuropeptides (calcitonin gene-related peptide, substance p, neurokin...
8452639 - Regulation of arginine vasopressin mrna in rat fetal hypothalamic cell culture. role of...
15145089 - Chronic cortisol suppresses pituitary and hypothalamic peptide message expression in pi...
8989239 - High expression of the pou factor brn3a in aggressive neuroendocrine tumors.
7643129 - Regulation of phenylethanolamine n-methyltransferase gene expression by imidazoline rec...
7968359 - Kindled seizures induce a long-term increase in vasopressin mrna.
9415489 - Developmental expression of h3.3a variant histone mrna in mouse.
23275439 - Gata-6 and nf-κb activate cpi-17 gene transcription and regulate ca2+ sensitization of...
21828099 - Ancestral functions of delta/notch signaling in the formation of body and leg segments ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2012-06-05
Journal Detail:
Title:  Microvascular research     Volume:  84     ISSN:  1095-9319     ISO Abbreviation:  Microvasc. Res.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-07-20     Completed Date:  2012-12-03     Revised Date:  2013-09-03    
Medline Journal Info:
Nlm Unique ID:  0165035     Medline TA:  Microvasc Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  155-60     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Affiliation:
Department of Physiological Sciences, Oklahoma State University, Stillwater, OK 74078, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anisomycin / pharmacology
Cells, Cultured
Child
Coronary Vessels / cytology,  drug effects,  metabolism
Endothelial Cells / drug effects,  metabolism
Enzyme Activation
Enzyme Activators / pharmacology
Female
Half-Life
Humans
Hydrogen Peroxide / pharmacology*
JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors,  metabolism
MAP Kinase Signaling System / drug effects
Male
Middle Aged
Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors,  metabolism
Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors,  metabolism
Muscle, Smooth, Vascular / drug effects*,  metabolism
Myocytes, Smooth Muscle / drug effects*,  metabolism
Oxidative Stress / drug effects
Pregnancy Proteins / genetics*,  metabolism
Promoter Regions, Genetic / drug effects
Protein Kinase Inhibitors / pharmacology
Protein Synthesis Inhibitors / pharmacology
RNA Processing, Post-Transcriptional / drug effects*
RNA Stability / drug effects
RNA, Messenger / metabolism*
Time Factors
Transfection
Up-Regulation
p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors,  metabolism
Grant Support
ID/Acronym/Agency:
R01 HL084494/HL/NHLBI NIH HHS; R01 HL084494/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Enzyme Activators; 0/Pregnancy Proteins; 0/Protein Kinase Inhibitors; 0/Protein Synthesis Inhibitors; 0/RNA, Messenger; 144589-93-5/placenta growth factor; 22862-76-6/Anisomycin; 7722-84-1/Hydrogen Peroxide; EC 2.7.11.24/JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24/MAPK1 protein, human; EC 2.7.11.24/Mitogen-Activated Protein Kinase 1; EC 2.7.11.24/Mitogen-Activated Protein Kinase 3; EC 2.7.11.24/p38 Mitogen-Activated Protein Kinases
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystro...
Next Document:  Interaction of FGF1 with a novel anti-angiogenic drug SSR128129E.